Genetic Variants Linked to Better Response to GLP-1 Medications for Obesity, Enabling Precision Treatment Approaches

Gene variants linked to how well GLP-1 receptor agonists work for weight loss and their side effects have been identified in a large study of people using these medications, offering a path toward more personalized obesity treatment.

The research, published in Nature Medicine on April 23, 2026, analyzed self-reported data from nearly 28,000 individuals who had taken GLP-1 drugs such as semaglutide (marketed as Wegovy and Ozempic) or tirzepatide (sold as Zepbound and Mounjaro). Scientists found a specific variant in the GLP1R gene, which encodes the receptor targeted by these medications, was associated with greater weight loss. Individuals with one copy of the variant, designated rs10305420, lost an average of about 1.7 pounds more than those without it, while those with two copies lost more than three pounds more.

The study also identified genetic connections to side effects. Variants in both the GLP1R and GIPR genes were linked to nausea or vomiting during treatment. Notably, the association with GIPR was observed only in people using tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist.

These findings provide direct genetic evidence that natural variation in the genes encoding the drug targets contributes to differences in how people respond to GLP-1 medications. The researchers incorporated these variants into a broader model that can stratify patients based on their predicted efficacy and risk of side effects, supporting the development of precision medicine strategies for obesity treatment.

Despite the effectiveness of GLP-1 receptor agonists in managing overweight and obesity, responses vary widely among individuals. Nearly one in four people experience little to no weight loss from these drugs, a variability that has puzzled scientists and frustrated patients. While the identified gene variants explain part of this difference, researchers noted they cannot fully account for why some people lose significantly more weight than others, indicating other factors are also involved.

The study builds on earlier work using genetic data from 23andMe participants and reinforces the role of pharmacogenomics in understanding drug response. By linking specific genetic markers to both therapeutic outcomes and adverse reactions, the research lays the groundwork for future approaches that could tailor GLP-1 therapy based on an individual’s genetic profile.